Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:0
članak: 8 od 1448  
Back povratak na rezultate
Vojnosanitetski pregled
2019, vol. 76, br. 10, str. 998-1006
jezik rada: engleski
vrsta rada: izvorni naučni članak
doi:10.2298/VSP171002191S

Creative Commons License 4.0
Faktori povezani sa poštovanjem preporuka dobre kliničke prakse tokom bolničkog lečenja bolesnika sa prvom epizodom oboljenja iz shizofrenog spektra
aClinic for Psychiatric Disorders "Dr Laza Lazarević", Belgrade
bClinic for Psychiatric Disorders "Dr Laza Lazarević", Belgrade + University of Pristina/Kosovska Mitrovica, Faculty of Medicine, Kosovska Mitrovica
cUniverzitet u Beogradu, Medicinski fakultet, Institut za farmakologiju, kliničku farmakologiju i toksikologiju
dUniverzitet u Beogradu, Medicinski fakultet, Institut za epidemiologiju

e-adresa: ivanastasevic73@gmail.com

Sažetak

Uvod/Cilj. Poštovanje smernica datih u vodičima dobre kliničke prakse tokom lečenja specifičnih poremećaja smatra se garancijom sprovođenja uniformne, na dokazima zasnovane kliničke prakse u psihijatriji. Cilj ovog rada bio je da se analizira usklađenost obrazaca propisivanja antipsihotičkih lekova sa preporukama dobre kliničke prakse u Srbiji i da se ostvari uvid u efekte koje je na propisivačku praksu u ovoj oblasti imalo donošenje Nacionalnog vodiča dobre kliničke prakse za dijagnostikovanje i lečenje shizofrenije. Metode. Neinterventna, opservaciona studija sprovedena je na Klinici za psihijatrijske bolesti "Dr Laza Lazarević" u Beogradu. Istraživanje je obuhvatilo uzastopni uzorak od 675 prethodno netretiranih bolesnika, lečenih hospitalno u periodu od 1. januara 2012. godine do 31. decembra 2015. godine, otpuštenih sa dijagnozom nekog od poremećaja iz shizofrenog spektra. Demografski podaci i podaci o kliničkim karakteristikama bolesnika, karakteristikama propisivača i propisanim antipsihoticima sakupljeni su retrospektivno, uvidom u medicinsku dokumentaciju bolesnika. Za analizu primarnih podataka korišćene su deskriptivne statističke metode i metode za testiranje statističkih hipoteza. Metoda logističke regresije korišćena je za identifikaciju faktora povezanih sa poštovanjem preporuka dobre kliničke prakse. Rezultati. Antipsihotičnom monoterapijom tretirano je 446 (66,1%) ispitanika. Nakon donošenja Nacionalnog vodiča dobre kliničke prakse za dijagnostikovanje i lečenje shizofrenije, propisivanje antipsihotične monoterapije antipsihoticima druge generacije bilo je značajno češće u odnosu na prethodni period (78,41% prema 63,5%; p < 0.001). Faktori nezavisno povezani sa poštovanjem preporuka dobre kliničke prakse su bili: starost ordinirajućeg lekara, starost i obrazovanje bolesnika i godina hospitalizacije. Zaključak. Nakon donošenja Nacionalnog vodiča dobre kliničke prakse za dijagnostikovanje i lečenje shizofrenije došlo je do značajnih, ali nedovoljnih promena u obrascima propisivanja antipsihotičke terapije tokom tretmana prve psihotične epizode u Srbiji.

Ključne reči

Reference

Novododat članak: provera, normiranje i linkovanje referenci u toku.
Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-43
Gelder GM, Andreas CN, Lopez-Ibor JJ, Geddes RJ. New Oxford Textbook of Psychiatry. 2nd ed. Oxford: Oxford University Press; 2009
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62(9): 975-83
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in firstepisode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162(10): 1785-804
Ito S, Nemoto T, Tsujino N, Ohmuro N, Matsumoto K, Matsuoka H, et al. Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. Eur Psychiatry 2015; 30(8): 995-1001
Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack HG, van der Linden JA, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002; 59(11): 1002-10
Roh D, Chang J, Yoon S, Kim C. Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison. Clin Psychopharmacol Neurosci 2015; 13(3): 275-82
Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996; 14(3 Suppl): 13S-21S
Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 Suppl 9: 5-9
Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998; 172(33): 53-9
Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J. Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurol Ther 2016; 5(2): 105-30
Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21(3): 419-29
Abdel-Baki A, Ouellet-Plamondon C, Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord 2012; 138 Suppl: S3-14
Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM, et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 2016; 77(4): 492-500
Lehman AF. Quality of care in mental health: the case of schizophrenia. Health Aff (Millwood) 1999; 18(5): 52-65
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(2 Suppl): 1-56
National Institute for health and Care Excellence (NICE). Clinical Guideline 178: Psychosis and Schizophrenia in Adults: Treatment and Management. London, UK; National Institute for health and Care Excellence; 2014
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr Bull 2010; 36(1): 94-103
Ministarstvo zdravlja Republike Srbije. Republička stručna komisija za izradu i implementaciju vodiča dobre kliničke prakse. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje shizofrenije. Belgrade; Ministarstvo zdravlja Republike Srbije; 2013. (Serbian)
World Health Organization. International classification of mental and behavioural disorders: Clinical description and diagnostic guidelines (ICD-10). Geneva: World Health Organization; 1992
Breitborde NJ, Srihari VH, Woods SW. Review of the operational definition for first-episode psychosis. Early Interv Psychiatry 2009; 3(4): 259-65
Register-Brown K, Hong LE. Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis. Schizophr Res 2014; 160(1-3): 20-6
Nielsen J, Le Quach P, Emborg C, Foldager L, Correll CU. 10-Year trends in the treatment and outcomes of patients with firstepisode schizophrenia. Acta Psychiatr Scand 2010; 122(5): 356-66
Pijnenborg GH, Timmerman ME, Derks EM, Fleischhacker WW, Kahn RS, Aleman A. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST). European Neuropsychopharmacology 2015; 25(6): 808-16
Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, et al. Medication prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. Am J Psychiatr 2015; 172(3): 237-48
Malaspina D. Schizophrenia: a neurodevelopmental or a neurodegenerative disorder. J Clin Psychiatry 2006; 67(8): e07
Marjanović D. Tranzicija mladih žena i muškaraca na tržištu rada Republike Srbije. Geneve: Međunarodna organizacija rada; 2016
Øhlenschlaeger J, Nordentoft M. Coercion in patients who at their first contact with the psychiatric services system were diagnosed within the schizophrenia-spectrum in Denmark. A register study. Nord J Psychiatry 2008; 62(1): 77-81
Large MM, Nielssen O. Violence in first-episode psychosis: a systematic review and meta-analysis. Schizophr Res 2011; 125(2-3): 209-20
Payne J, Malla A, Norman R, Windell D, Nicole B. Status of firstepisode psychosis patients presenting for routine care in a defined catchment area. Can J Psychiatry 2006; 51(1): 42-7
Souaiby L, Gaillard R, Krebs MO. Duration of untreated psychosis: A state-of-the-art review and critical analysis. Encephale 2016; 42(4): 361-6
Marić N, Đorđević A, Samardžić R, Jašović-Gašić M. Antipsihotici - ka jedinstvenom poređenju doziranja. Psihijat dan 2000; 32(2-3): 95-103
Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2014; 205(2): 88-94
Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlaeger J, Le Quach P, et al. Course of illness in a sample of 265 patients with first-episode psychosis--five-year follow-up of the Danish OPUS trial. Schizophr Res 2009; 107(2-3): 173-8
Nielssen O, Yee N, Millard M, Large M. Comparison of First-Episode and Previously Treated Persons With Psychosis Found NGMI for a Violent Offense. Psychiatric Services 2011; 62(7): 759-64
Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, et al. Eufest Study Group. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 2013; 23(3): 196-204
Compton MT, Gordon TL, Goulding SM, Esterberg ML, Carter T, Leiner AS, et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized firstepisode patients. J Clin Psychiatry 2011; 72(2): 225-32
Marshall M, Husain N, Bork N, Chaudhry IB, Lester H, Everard L, et al. Impact of early intervention services on duration of untreated psychosis: Data from the National EDEN prospective cohort study. Schizophr Res 2014; 159(1): 1-6
Farooq S, Large M, Nielssen O, Waheed W. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: A systematic review and meta analysis. Schizophr Res 2009; 109(1-3): 15-23
Zhang J, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013l; 16(6): 1205-18
Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, et al. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 2014; 17(1): 41-51
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia. Am J Psychiatry 2011; 168(6): 603-9
Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A, et al. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. Int J Neuropsychopharmacol 2016; 19(4): pii: pyv121
Tungaraza TE, Ahmed W, Chira C, Turner E, Mayaki S, Nandhra HS, et al. Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a crosssectional survey of early intervention teams. Ther Adv Psychopharmacol 2017; 7(3): 103-11
Divac N, Todorović Z, Stojanović R, Nešić Z, Jašović-Gašić M, Lečić-Tosevski D, et al. Utilization of psychiatric drugs in Serbia. Vojnosaniti Pregl 2009; 66(3): 233-7